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Fistula use for dialysis is less frequent among obese than
non-obese patients. This discrepancy may be due to a lower
rate of fistula placement in obese patients, a higher primary
failure rate (fistulas that are never usable for dialysis), or a
higher secondary failure rate (fistulas that fail after being
used successfully for dialysis). Using a prospective,
computerized vascular access database, we identified all
patients receiving a first fistula or graft at our institution
during a 2-year period. The access outcomes were compared
between obese (body mass index (BMI) X30 kg/m2) and
non-obese (BMIo30 kg/m2) patients. Fistula placement was
equally likely between obese and non-obese patients (47.4 vs
47.1%). The primary failure rate of fistulas was similar in both
groups (46 vs 41%, P¼ 0.45). Among those fistulas that were
usable for dialysis, the secondary survival was worse in obese
patients (hazard ratio 2.74; 95% confidence interval (CI),
1.48–7.90; P¼ 0.004). Secondary fistula survival in obese vs
non-obese patients was 68 vs 92% at 1 year, 59 vs 78% at 2
years, and 47 vs 70% at 3 years. On multiple variable survival
analysis with age, sex, race, diabetes, coronary artery disease,
peripheral vascular disease, fistula location, surgeon, and
obesity in the model, obesity was the only significant factor
predicting secondary fistula failure (hazards ratio 2.93; 95%
CI, 1.44–5.93; P¼ 0.004). In conclusion, long-term fistula
survival is worse in obese than non-obese patients, owing to
a higher secondary failure rate.
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Several clinical studies have reported a lower prevalence of
fistulas among obese hemodialysis patients, as compared to
their non-obese cohorts.1–3 Increasing the prevalence of
fistulas requires increasing fistula placement, adequate
maturation of new fistulas, and successful long-term
cannulation of the fistulas by the dialysis staff.4 Thus, there
are several potential explanations for the lower fistula
prevalence among obese patients. First, it is possible that
fistulas are less likely to be placed in obese patients. Second,
fistulas placed in obese patients may be more likely to have a
primary failure (never be usable for dialysis). Third, fistulas
in obese patients may be more likely to have a secondary
failure after initially being used successfully for dialysis. The
published studies, owing to their cross-sectional research
design, cannot adequately distinguish among these three
potential scenarios. Such an analysis would require long-
itudinal follow-up of fistulas placed in obese and non-obese
patients with chronic kidney disease.
The goal of the present study was to compare the
outcomes of arteriovenous fistulas placed in obese and
non-obese patients, and to elucidate the reasons for the lower
fistula use among obese patients.
RESULTS
During the 2-year study period, a first fistula was placed in
183 patients and a first graft in 205 patients. Thus, among the
first vascular accesses placed, 47.2% were fistulas. As
compared to patients with graft placement, those receiving
a fistula were more likely to be male and white (Table 1).
However, patient age, frequency of diabetes, coronary artery
disease, peripheral vascular disease, and obesity did not differ
significantly between patients receiving a fistula and those
receiving a graft. Fistula placement was equally likely in the
obese and non-obese patient groups (47.4 vs 47.1%,
respectively, of vascular accesses placed). On multiple logistic
regression analysis, only two clinical factors predicted a lower
likelihood of fistula placement: black race (odds ratio (OR)
0.50; 95% confidence interval (CI), 0.30–0.86) and female sex
(OR 0.60; 95% CI, 0.40–0.90).
The fistula study population included 54 obese and 129
non-obese patients. The clinical characteristics of both
groups are compared in Table 2. The obese patients were
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similar to the non-obese patients in terms of their age, sex,
race, frequency of coronary artery disease and peripheral
vascular disease. The likelihood of fistula placement before
dialysis was similar in both groups, as was the fistula location
and frequency of vein transposition. However, diabetes was
more common among the obese patients. On multiple
logistic regression analysis, the only variable that was
associated with obesity was the presence of diabetes (OR
3.30; 95% CI, 1.61–6.74).
The diameters of the arteries and veins used to create the
fistulas were similar between the obese and non-obese patient
groups, whether one examined forearm or upper arm fistulas
(Table 3). Primary fistula failure (inability to ever use the
fistula for dialysis, owing to technical failure, early thrombo-
sis, or failure to mature) occurred at a similar rate in the two
groups (Table 4). However, among those patients whose
fistulas were successfully used for dialysis for at least 1 month,
the secondary fistula survival was substantially lower in obese
patients, as compared with their non-obese controls
(Figure 1). The hazard ratio for secondary fistula failure in
obese patients was 2.74 (95% CI, 1.48–7.90; P¼ 0.004).
Secondary fistula survival did not differ between overweight
(body mass index (BMI) 25.0–29.9 kg/m2) and normal weight
(BMI 18.5–24.9 kg/m2) patients (hazard ratio, 1.13; 95% CI,
0.42–3.06; P¼ 0.80) (Figure 1). On multiple variable survival
analysis with age, sex, race, diabetes, coronary artery disease,
peripheral vascular disease, fistula location, surgeon, and
obesity in the model, obesity was the only significant factor
associated with secondary fistula failure (hazards ratio 2.93;
95% CI, 1.44–5.93; P¼ 0.004). To evaluate the possibility that
the hazard of fistula failure differs over time, a time-
by-obesity interaction variable was defined, and the Cox
model re-estimated after adding this variable. The interaction
variable yielded a P-value of 0.065.
DISCUSSION
The present study examined the reasons for a lower
arteriovenous fistula prevalence among obese hemodialysis
patients. Fistula placement could not account for this
Table 1 | Clinical features of patients receiving a fistula vs a
graft
Fistula Graft P-value
N patients 183 205 —
Age 55714 55715 0.71
Sex 0.007
Male 109 (60%) 94 (46%) —
Female 74 (40%) 111 (54%) —
Race 0.01
Black 139 (76%) 178 (87%) —
White 42 (24%) 27 (13%) —
Diabetes 0.56
Yes 107 (58%) 112 (55%) —
No 79 (42%) 93 (45%) —
CAD 0.12
Yes 55 (30%) 77 (38%) —
No 128 (70%) 128 (62%) —
PVD 0.86
Yes 23 (12%) 27 (13%) —
No 160 (88%) 178 (87%) —
Obese 0.96
Yes 54 (30%) 60 (29%) —
No 129 (70%) 145 (71%) —
CAD, coronary artery disease; PVD, peripheral vascular disease.
Table 2 | Clinical features of fistula study patients
Obese Non-obese P-value
N patients 54 129 —
Age 56712 56716 0.92
Sex 0.09
Male 27 (50%) 82 (64%) —
Female 27 (50%) 47 (36%) —
Race 0.17
Black 45 (83%) 94 (73%) —
White 9 (17%) 33 (27%) —
Diabetes 0.0007
Yes 41 (76%) 63 (49%) —
No 13 (24%) 66 (51%) —
CAD 0.25
Yes 13 (24%) 42 (33%) —
No 41 (76%) 87 (67%) —
PVD 0.55
Yes 8 (15%) 15 (12%) —
No 46 (85%) 114 (88%) —
Pre-HD? 0.33
Yes 26 (48%) 52 (40%) —
No 28 (52%) 77 (60%) —
Fistula location 0.90
Forearm 29 (54%) 68 (53%) —
Upper arm 25 (46%) 61 (47%) —
Vein transpositiona 0.45
Yes 8 (15%) 14 (11%) —
No 46 (85%) 115 (89%) —
CAD, coronary artery disease; Pre-HD, fistula placed before initiation of dialysis; PVD,
peripheral vascular disease.
aTransposition of the vein, either as a primary fistula procedure or as a second
procedure for fistulas that were too deep for safe cannulation.
Table 3 | Preoperative vascular diameters in obese and
non-obese patients, sorted by fistula location
Obese patients Non-obese patients P-value
Forearm fistula
Artery diameter 0.2670.04 0.2670.04 0.98
Vein diameter 0.3170.05 0.3170.04 0.83
Upper arm fistula
Artery diameter 0.4870.08 0.4970.09 0.88
Vein diameter 0.4470.11 0.4170.09 0.24
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difference, as the proportion of obese and non-obese patients
having a fistula placement was virtually identical. Although
obesity may make it more challenging for the surgeon to
identify suitable vessels for fistula construction, this problem
can be overcome by the routine use of preoperative vascular
mapping. We have previously documented that the frequency
of fistula placement was similar in obese and non-obese
patients when vascular mapping was employed.5 A second
potential explanation for the lower prevalence of fistulas
among obese patients is that new fistulas are less likely to
mature adequately for successful cannulation for dialysis.
This explanation also seems unlikely, given that the primary
failure rate of new fistulas was very similar between obese and
non-obese patients (Table 4). This observation is in keeping
with a previous report from our institution finding that
successful initial use of fistulas for dialysis was equally likely
in obese and non-obese dialysis patients.5
Finally, it is possible that the secondary failure rate of
fistulas (after initial successful use for dialysis) is higher
among obese patients. This hypothesis was confirmed by
comparing the cumulative survival rates of fistulas in the two
study groups (Figure 1). The inferior survival of fistulas in
obese patients was evident within the first few months, and
sustained for at least 3 years. Why might fistulas failure be
more likely in obese patients? One potential explanation is
that fistulas created in obese patients utilized smaller vessels,
as compared with fistulas placed in non-obese patients. This
seems unlikely, given the similarity between the arterial and
venous diameters in the two patient groups (Table 3). A
second possibility is that obese patients may require vein
transposition for fistula creation more frequently, and
transposed vein fistulas have secondary survival inferior to
that obtained in fistulas using veins in their native location.6
However, in the present study, there was no difference in the
proportion of obese and non-obese patients requiring vein
transposition for fistula creation (Table 2). A third potential
explanation is that secondary fistula failure is more likely in
obese patients as a consequence of needle infiltration during
cannulation. However, a recent report from our institution
found no difference in the frequency of fistula infiltration
between obese and non-obese patients.7 A fourth possibility
is that a hypercoagulable state in obese patients increases the
likelihood of fistula thrombosis. This hypothesis would be
consistent with the increased tendency for early fistula
thrombosis (56 vs 38%, P¼ 0.13) in obese patients with
primary fistula failure (Table 4). All secondary fistula failures
were due to thrombosis. Very few of the clotted fistulas
underwent attempted thrombectomy. Thus, it was not
possible to determine whether the excess fistula failure in
the obese patients was due to a hypercoagulable state or to
accelerated neointimal hyperplasia.
A final possibility is that myointimal hyperplasia is more
aggressive in obese than non-obese patients, and that this
results in earlier onset of stenosis, leading to fistula
thrombosis. This hypothesis would be consistent with the
association between obesity and increased plasma levels of
the inflammatory marker, C-reactive protein, which has been
observed in both the normal population,8,9 as well as in
patients with chronic kidney disease or dialysis.10,11 More-
over, a preliminary report suggested a pathogenetic role for
C-reactive protein in the induction of myointimal hyperpla-
sia.12 The retrospective nature of the present study precluded
an evaluation of the association between C-reactive protein
levels and secondary fistula failure. The expanded Cox model
did not show a significant interaction between time and the
effect of obesity on secondary fistula failure (P¼ 0.065).
However, the suggestion that the hazard for fistula failure is
greatest in the first 6 postoperative months merits future
investigation.
There was no difference in secondary fistula survival
between overweight and normal weight patients (Figure 1).
This observation suggests that mild increases in BMI do not
represent a risk factor for fistula failure. Thus, only
substantial increases in BMI (X30 kg/m2) appear to increase
the likelihood of secondary fistula failure.
Because this study represents the fistula outcomes from a
single dialysis center, the findings may not generalize to all
dialysis centers. For example, in centers not using routine
preoperative vascular mapping, the frequency of fistula
placement may be lower in obese, as compared to non-
obese, patients. Moreover, preoperative vascular mapping
Table 4 | Initial fistula outcomes
Obese Non-obese
Total number 54 129
Successful use for dialysis (X1 month) 29 (54%) 76 (59%)
Primary failure 25 (46%) 53 (41%)
Technical failure 5 7
Early thrombosis 14 20
Failure to mature 6 25
Steal 0 1
No difference in outcomes between groups, P=0.45.
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Figure 1 | Secondary survival of fistulas in obese and non-obese
patients. Secondary survival was calculated from fistula placement to
permanent fistula failure, after excluding fistulas with primary failure
(never usable for dialysis). Obese, BMI 430 kg/m2; overweight, BMI
25.0–29.9 kg/m2; normal weight, BMI 18.5–24.9 kg/m2. We omitted
seven patients who were underweight (BMIo18.5). P¼ 0.004 for
obese vs non-obese patients, and P¼ 0.80 for overweight vs normal
weight patients, by log rank test.
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may affect the risk of fistula failure in obese patients. A
previous analysis from our center, at a time when
preoperative vascular mapping was not being performed,
observed a trend for higher primary fistula failure (non-
maturation) in obese, as compared with non-obese patients
(65 vs 45%, P¼ 0.07).13 In contrast, following the imple-
mentation of routine preoperative mapping, we no longer
observed such an effect (primary fistula failure in obese vs
non-obese patients, 48 vs 43%, P¼ 0.61).5 Similarly, three
subsequent studies from centers using preoperative vascular
mapping found no association between BMI and risk of
primary fistula failure.14–16 In contrast to the present study,
the one by Dixon et al.14 found no association between BMI
and secondary fistula failure. The patients in that study were
predominantly (490%) white, whereas the ones enrolled in
the current study were predominantly black. Thus, obesity
may be a risk factor for secondary fistula failure in black, but
not white patients. Owing to the small number of white
patients in the present study, it is difficult to assess this
potential explanation for the discrepant findings. Finally,
another observational study found no association between
BMI and secondary fistula failure;17 it was not stated,
however, whether preoperative vascular mapping had been
used.
Regardless of the precise mechanism involved, the
association between obesity and inferior fistula outcomes
has important clinical implications. This discrepancy may in
part explain some geographic discrepancies in fistula
prevalence. For example, the Dialysis Outcomes and Practice
Pattern Study reported that obesity was more common in the
USA than in Europe,2 and this may, in part, contribute to the
lower prevalence of fistulas in the USA. From a practical
point of view, obese patients receiving an arteriovenous
fistula may require heightened vigilance for evidence of
fistula stenosis, and may derive the greatest benefit from
potential pharmacologic prophylaxis.
MATERIALS AND METHODS
Patient population
About 450 patients receive chronic hemodialysis under the care of
University of Alabama at Birmingham nephrologists. These patients
receive dialysis at one of five dialysis units in the metropolitan
Birmingham area. Initial vascular access placements and subsequent
access revisions are performed by University of Alabama at
Birmingham transplant surgeons and interventional radiologists or
nephrologists.
Vascular access management
Four surgeons performed all the vascular access operations. Each
patient referred for a new vascular access first underwent
preoperative sonographic vascular mapping. The results of the
vascular mapping studies were provided to the surgeons, to assist
them in planning the optimal access type and location.4,5,18 Creation
of a fistula required a minimum artery diameter of 2.0 mm, a
minimum vein diameter of 2.5 mm, and absence of stenosis or
thrombosis of the vein proximal to the intended anastomotic site.
The type of fistula placed, in order of preference, was a radiocephalic
fistula, brachiocephalic fistula, or transposed brachiobasilic fistula.
In some patients, a vein transposition (superficialization) was
performed as a second surgical procedure if the fistula was too deep
for safe cannulation. Grafts were placed only when there were no
suitable vessels for creation of a fistula. All patients were referred for
creation of a vascular access, regardless of their degree of obesity. All
access procedures were scheduled by two full-time vascular access
coordinators, who recorded the procedures in a prospective
computerized database.19
The surgeons usually evaluated each patient’s new fistula 1–2
weeks following its creation. In addition, new fistulas were assessed
clinically for their maturation and suitability by the nephrologists
and dialysis nurses. If there was uncertainty about the suitability of a
fistula for cannulation, a postoperative ultrasound was obtained to
measure the diameter of the fistula, the access blood flow, and the
depth from the skin. In general, a fistula was considered to be
adequately developed if the ultrasound measurements included a
diameter X4 mm, blood flow X500 ml/min, and perpendicular
distance from the skin p5 mm.20 In addition, the ultrasound was
used to screen for potentially remediable causes of immature
fistulas. These included stenotic lesions, large competing veins, or
fistulas that were too deep to be cannulated safely.21 The ultrasound
findings were followed in some patients by specific salvage
procedures by the surgeon or radiologist. These could include
angioplasty or surgical revision of a stenotic lesion, ligation of a
competing vein, or superficialization of a deep fistula. Fistulas were
usually cannulated for dialysis 8–12 weeks following their creation. If
an immature fistula had no remediable lesions or failed to develop
despite the salvage procedure, the patient was referred to the
surgeon for placement of a new vascular access.
Patients in whom there was a clinical suspicion of fistula stenosis
were referred for a diagnostic fistulogram. The clinical criteria
included abnormalities in physical examination, difficulties in the
dialysis treatment, or an unexplained decrease in Kt/V.
22 A X50%
stenotic lesion was considered hemodynamically significant and
treated by angioplasty. Elective surgical revision was performed if
the angioplasty was technically unsatisfactory. A fistula that could
not be salvaged either radiologically or surgically was abandoned,
and the patient was referred for placement of a new vascular access.
Data collection and analysis
The prospective access database was used to identify a comprehen-
sive list of all vascular accesses placed during a 2-year time period
(1 January 2002 to 31 December 2003). It was also used to track
subsequent surgical or radiologic interventions for each access
placed. Each patient’s medical record was reviewed for research
purposes after obtaining Institutional Review Board approval.
Fistulas were considered adequate for dialysis if they were
cannulated successfully for dialysis with two needles for at least
1 month, and within 6 months of their creation.13 A technical failure
was defined as the inability of the surgeon to construct a vascular
access or thrombosis within 24 h of its creation. Early thrombosis
was defined if a fistula clotted within 12 weeks of its creation, and
before being used for dialysis. Fistulas were deemed to have failed to
mature, if they were not usable for dialysis within 6 months of
placement, in the absence of technical failure or early thrombosis.
Fistulas were deemed inadequate for dialysis (or primary failures) if
there was a technical failure, early thrombosis, or failure to mature.
The fistula outcome was considered indeterminate if the patient had
not started dialysis at the time of data analysis or if the patient died,
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moved to a non-participating dialysis unit, was lost to follow-up, or
switched to peritoneal dialysis before the adequacy for dialysis could
be assessed. Secondary failure was defined as permanent failure of a
fistula, after it had achieved primary adequacy for dialysis.
Demographic and clinical information was collected on each
patient, including age, sex, race, and presence of diabetes, coronary
artery disease, or peripheral vascular disease. BMI was calculated
from standard formulae. Patients were considered obese if their BMI
was X30 kg/m2, and non-obese if their BMI was o30 kg/m2.
During the 2-year study period, 262 fistulas were placed in 226
patients. For the purpose of this study, only the first fistula placed in
each patient was included in the analysis. We excluded 29 patients
with indeterminate fistula outcomes, and 14 with unknown or
indeterminate BMI. The remaining 183 patients constituted the
fistula study population. During the same study period, 205 first
grafts were placed, and these patients constituted the graft study
population. Thus, among all first permanent accesses placed during
the study period, 47% were fistulas and 53% were grafts.
Statistical analyses
The clinical characteristics were compared between obese and non-
obese patients using Student’s t-tests or w2 analysis, with a P-value
o0.05 considered to be statistically significant. Multiple logistic
regression analysis was used to evaluate which factors were
associated with fistula placement and with obesity. Secondary fistula
survival was calculated from the date of fistula creation to the date
of permanent failure, regardless of the number of interventions
required to achieve long-term patency. Survival analysis techniques
were used to model fistula survival time, and the log rank test used
to compare the survival of patient subgroups. Univariate Cox
proportional hazard models were fit. Hazard ratios and their
associated 95% CI were computed. Finally, multiple variable survival
analysis was used to model the association between the clinical
variables and secondary fistula survival.
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